RT Journal Article
SR Electronic
T1 Fine-mapping of melanoma-associated genomic regions identifies novel causal SNPs in the <em>MTAP/CDKN2A</em> and <em>CASP8</em> loci
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.17.21260620
DO 10.1101/2021.07.17.21260620
A1 Castaneda-Garcia, Carolina
A1 Iyer, Vivek
A1 Nsengimana, Jérémie
A1 Trower, Adam
A1 Droop, Alastair
A1 Brown, Kevin M
A1 Choi, Jiyeon
A1 Zhang, Tongwu
A1 Harland, Mark
A1 Newton-Bishop, Julia A.
A1 Bishop, D. Timothy
A1 Adams, David J.
A1 Iles, Mark M.
A1 Robles-Espinoza, Carla Daniela
YR 2021
UL http://medrxiv.org/content/early/2021/07/22/2021.07.17.21260620.abstract
AB A number of genomic regions have been associated with melanoma risk through genome-wide association studies, however, the causal variants underlying the majority of these associations remain unknown. Here, we sequenced either the full locus or the functional regions including exons of 19 melanoma-associated loci in 1,977 British melanoma cases and 754 controls. Variant filtering followed by Fisher's exact test analyses identified 88 variants associated with melanoma risk. Sequential conditional logistic regressions identified the distinct haplotypes on which variants lie, and massively parallel reporter assays (MPRA) provided biological insights into how these variants influence gene function. We performed further analyses to link variants to melanoma risk phenotypes and assess their association with melanoma-specific survival. Our analyses replicate previously known associations in the MC1R and TYR loci, while identifying novel potentially causal variants at the MTAP/CDKN2A and CASP8 loci. These results increase our understanding of the architecture of melanoma risk and outcome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Cancer Research UK [to D.J.A.], the Medical Research Council [MR/S01473X/1 to C.D.R.-E. and D.J.A] and Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT UNAM) [IA202020 to C.D.R.-E.]. C.D.R.-E. is also supported by CONACyT [A3-S-31603 and A1-S-30165], the Melanoma Research Alliance [825924, https://doi.org/10.48050/pc.gr.143729], the Academy of Medical Sciences through a Newton Advanced Fellowship [NAF\R2\180782] and a Wellcome Sanger Institute International Fellowship. C.C.G. is a PhD student from Programa de Doctorado en Ciencias Biomedicas, Universidad Nacional Autonoma de Mexico (UNAM), and is supported by CONACyT [holder no. 330123, scholarship no. 385365]. This work represents a substantial part of her dissertation. Funding for the project was provided by the Wellcome Trust under award 076113.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the Leeds Melanoma Cohort Study was granted by the North East - York Research Ethics Committee (MREC 1/3/57), the Patient Information Advisory Group (PIAG 3-09(d)/2003), and further approved by the Sanger Institute Human Materials and Data Management Committee. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data for all cases and controls in this study have been deposited at the European Genome-phenome Archive and can be found under accession number EGAC00001000205. All code used in this study can be found in https://github.com/citosina/melanoma_reseq. MPRA data are available in the NCBI Gene Expression Omnibus as a SuperSeries under the accession number GSE129250.https://github.com/citosina/melanoma_reseq